
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a late-stage clinical biotechnology company developing innovative nanoparticle-based therapies for cancer treatment, with lead program NBTXR3 showing promising results in Phase II/III trials for soft-tissue sarcoma and in ongoing Phase III trials for elderly, cisplatin-ineligible patients with locally advanced squamous-cell carcinoma of the head and neck (LA HNSCC). The company's collaboration with JNJ and the potential for significant royalties and milestones adds to the positive outlook, although risks such as clinical trial failures and regulatory setbacks should be considered. The company is also facing financial risks, with meaningful debt on its balance sheet and potential need for additional financing before turning cash flow positive.
Bears say
Nanobiotix is a late-stage clinical biotechnology company with a promising pipeline and strong operational progress. However, the company's novel radioenhancer, NBTXR3, presents clinical and commercial risks and the data is still in the early stages. There are upcoming milestones and catalysts to keep an eye on, but overall, the company's cash runway is extended into 2029, providing some stability.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares